Graybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare Conference
Graybug Vision, a clinical-stage biopharmaceutical company, announced CEO Fred Guerard will participate in a fireside chat ahead of the virtual Piper Sandler Healthcare Conference on December 1-3, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Graybug Vision, a clinical-stage biopharmaceutical company, announced CEO Fred Guerard will participate in a fireside chat ahead of the virtual Piper Sandler Healthcare Conference on December 1-3, 2020. The recorded chat will be accessible starting November 23, 2020, via the company's website and will remain available for 14 days post-conference. Graybug focuses on developing innovative treatments for retinal diseases, utilizing proprietary ocular delivery technologies for extended drug release, including lead candidate GB-102 for age-related macular degeneration.
Details
News Market Reaction – GRAY
The recorded move for GRAY in the trading session of this news was +2.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a fireside chat in advance of the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020.
A recording of the fireside chat will be accessible beginning November 23, 2020 by visiting IR Events & Presentations in the Investors and Media section of the company’s website at https://investors.graybug.vision/news-events/events-presentations. The recording will be available on the Graybug website for 14 days following the conference.
About Graybug Vision
Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug’s lead product candidate, GB-102, a microparticle depot formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate, targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug is also using its proprietary technologies to develop GB-401, an injectable depot formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer, and GB-103, a longer-acting version of GB-102, designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug is headquartered in Redwood City, California. For more information, please visit www.graybug.vision.
| Investor Contact IR@graybug.vision (650) 487-2409 | Media Contact media@graybug.vision (404) 384-0067 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.